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Mutations in1-acylglycerol-3-phosphate-O-acyltran-
sferase 2 (AGPAT2) cause congenital generalized lip-
odystrophy. To understand the molecular mecha-
nisms underlying the metabolic complications
associated with AGPAT2 deficiency, Agpat2 null
mice were generated. Agpat2/ mice develop
severe lipodystrophy affecting both white and brown
adipose tissue, extreme insulin resistance, diabetes,
and hepatic steatosis. The expression of lipogenic
genes and rates of de novo fatty acid biosynthesis
were increased 4-fold in Agpat2/ mouse livers.
The mRNA and protein levels of monoacylglycerol
acyltransferase isoform 1 were markedly increased
in the livers of Agpat2/ mice, suggesting that the
alternativemonoacylglycerol pathway for triglyceride
biosynthesis is activated in the absence of AGPAT2.
Feeding a fat-free diet reduced liver triglycerides
by 50% in Agpat2/ mice. These observations
suggest that both dietary fat and hepatic triglyceride
biosynthesis via a monoacylglycerol pathway may
contribute to hepatic steatosis in Agpat2/mice.
INTRODUCTION
The 1-acylglycerol-3-phosphate-O-acyltransferases (AGPATs)
are members of the acyltransferase family of enzymes, with ten
putative isoforms based on amino acid sequence homology
(Agarwal et al., 2003, 2006, 2007; Cao et al., 2006; Leung,
2001; Li et al., 2003; Tang et al., 2006; Ye et al., 2005). AGPATs
catalyze the conversionof lysophosphatidic acid (LPA, 1-acylgly-
cerol-3-phosphate) to phosphatidic acid (PA, 1,2 diacylglycerol-
3-phosphate) by esterifying a fatty acyl group at the sn-2 position
of theglycerol backbone and thusplay acritical role in thebiosyn-Cethesis of glycerophospholipids and triacylglycerols (TGs) from
glycerol-3-phosphate (Leung, 2001; West et al., 1997). Few of
theseAGPATshave additional acyltransferase activity (Table S1).
The biological relevance of the different AGPAT isoforms
remains largely unknown except for AGPAT2 and AGPAT6/
GPAT4 (Agarwal and Garg, 2003; Beigneux et al., 2006; Chen
et al., 2008; Vergnes et al., 2006). A role for AGPAT2 in
TG synthesis and adipocyte biology has emerged since we
discoveredmutations inAGPAT2 that causeanautosomal reces-
sively inherited form of congenital generalized lipodystrophy
(CGL) type 1 (Agarwal et al., 2002). Patients with CGL are born
with near-complete absence of adipose tissue and are prone to
developing metabolic complications associated with insulin
resistance, such as impaired glucose tolerance, diabetes, hyper-
triglyceridemia, and hepatic steatosis, early in life (Agarwal and
Garg, 2006; Garg, 2004). High expression of AGPAT2 in the
adipose tissue may explain the lack of adipose tissue in CGL
(Agarwal et al., 2002); however, whether the lack of AGPAT2
activity causes lipodystrophy by impairing TG synthesis in the
adipocytes or by affecting adipocyte differentiation (Gale et al.,
2006) remains unclear. Furthermore, the underlying molecular
mechanisms involved in the development ofmetabolic complica-
tions in these patients have not been elucidated. Therefore, to
better understand themolecular basis of themetabolic complica-
tions due to AGPAT2 deficiency, we generated Agpat2 null mice
and characterized the biochemical and molecular alterations
related to the metabolic complications observed in these mice.
RESULTS
Gene Knockout Strategy and Phenotypic
Characterization
The strategy used to disrupt Agpat2 in mice is shown in
Figure 1A. A targeting vector containing the neomycin resistance
gene was used to replace a portion of the proximal promoter and
exons 1–4 of Agpat2. The mouse genotype was confirmed by
PCR using genomic DNA (Figure S1A), and the absence of thell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc. 165
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Lipodystrophy in AGPAT2-Deficient MiceFigure 1. Agpat2/ Mice Have Markedly Reduced Total Hepatic AGPAT Activity, Complete Lack of Adipose Tissue, and Abnormal Energy
Metabolism
(A) Strategy to disrupt Agpat2 in mice. The map of the wild-type allele is shown for exons 1–6 of Agpat2. The genomic sequence spanning a portion of the
promoter and exons 1–4 were replaced with the neomycin resistance cassette (Neo). Herpes simplex virus thymidine kinase, HSV-TK.
(B) Total AGPAT activity in the liver homogenates of the Agpat2/mice revealed significantly reduced activity (10% of that measured in wild-type mouse livers).
Livers from six Agpat2/ mice and six wild-type mice were studied. Bars represent the mean and SEM.
(C) Magnetic resonance imaging of the male and female wild-type and Agpat2/mice. Coronal sections were obtained on the whole-body midsection for three
male and three femaleAgpat2/ and threemale and three female wild-typemice. Thewild-typemice show adipose tissue in the subcutaneous and intra-abdom-
inal regions as areas of increased signal intensity on T-1 weighted images. The Agpat2/ mice in contrast have no adipose tissue.166 Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc.
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Lipodystrophy in AGPAT2-Deficient MiceTable 1. Phenotypic Comparison of Wild-Type and Agpat2/ Mice
Gender Male Female
Genotype Wild-type Agpat2/ Wild-type Agpat2/
Number of mice 10 10 10 10
Body weight (g) 25.9 ± 2.4 24.7 ± 4.4 25.9 ± 3.6 25.6 ± 3.6
Liver weight (g) 1.40 ± 0.19 3.52 ± 0.67* 1.43 ± 0.29 4.1 ± 1.1*
Liver TGs (mg/g) 7.5 ± 2.7 48.2 ± 17.4* 18.1 ± 9.4 37.4 ± 18.8*
Plasma TGs (mg/dl) 83 ± 23 153 ± 48* 84 ± 26 105 ± 23
Plasma insulin (ng/ml) 0.8 ± 0.4 49.0 ± 48.0* 0.9 ± 0.4 66.4 ± 49.7*
Plasma glucose (mg/dl) 303 ± 54 428 ± 75* 286 ± 85 428 ± 113*
Plasma FFA (mEq/l) 0.53 ± 0.13 0.55 ± 0.10 0.54 ± 0.18 0.37 ± 0.12*
WAT weight1 (g) 0.24 ± 0.01 0* 0.37 ± 0.09 0*
BAT weight1 (g) 0.05 ± 0.01 0* 0.08 ± 0.01 0*
Plasma leptin1 (ng/ml) 2.23 ± 0.34 0.41 ± 0.05* 4.02 ± 2.13 0.21 ± 0.28*
Mice (11–15weeks of age) were fed a standard rodent chow and killed in the nonfasted state. Each value represents themean ± SD. * denotes a level of
statistical significance of p < 0.05 between the wild-type and Agpat2/ mice. WAT, epididymal and perigonadal white adipose tissue for male and
female mice respectively; BAT, brown adipose tissue; FFA, free fatty acids; TG, triglycerides.
1 These observations were made in five animals from each group.Agpat2 mRNA transcript was confirmed using real-time quanti-
tative PCR (Figure S1B). Furthermore, total AGPAT activity was
reduced by 90% in the liver homogenates as measured by
conversion of [3H]LPA to [3H]PA (Figure 1B). Matings between
Agpat2+/ mice produced offspring born in the expected
Mendelian 1:2:1 ratio; however, 80% of the Agpat2/ pups
died by 3 weeks of age. Equal numbers of male and female
Agpat2/ mice survived past weaning and had body weights
similar to littermate gender-matched wild-type mice (Table 1).
The majority of mice that did not reach weaning died during
the first week of life. The exact cause of the increased mortality
is not known, but two likely contributors are: (1) hyperglycemia
resulting in volume depletion, which we could document as early
as day 1 after birth (data not shown); and (2) hypothermia, which
could occur as a result of lack of body fat.
Lipodystrophic Features
The characterization of the Agpat2/mice revealed some inter-
esting features in addition to those previously observed in human
CGL. Both male and female Agpat2/ mice had a complete
absence of white and brown adipose tissue. Whole-body
[1H]magnetic resonance spectroscopy showed that Agpat2/
mice had 2% body fat compared to 24%–29% in the wild-type
mice (Figure S2). MR imaging (Figure 1C) revealed subcutaneous
and intra-abdominal fat in the wild-type mice, but total lack of
these depots in the Agpat2/ mice.
Compared to the age-matched wild-type mice, dissection of
8- to 10-week-old Agpat2/ male and female mice revealed
generalized organomegaly, including enlarged kidneys (mean ±
SD; 0.96 ± 0.1 g versus 1.3 ± 0.1 g, respectively; p < 0.05),
enlarged spleens (0.09 ± 0.02 g versus 0.17 ± 0.05 g, respec-
tively; p < 0.05), and elongated small intestines (29.2 ± 4.9 cm
versus 41.2 ± 7.9 cm, respectively; p < 0.05) (Figure S3). The liver
weight was more than two times larger in both genders of
Agpat2/ mice (Table 1), and liver histology revealed hepatic
steatosis (Figures S4 and S5).
The Agpat2/ mice also had markedly enlarged pancreatic
islets as seen with hematoxylin and eosin staining (Figure S6).
Immunostaining with anti-insulin and anti-glucagon antibodies
showed that the enlarged islets were composed of excess of
b cells, without significant changes in a cells (Figure S6).
Metabolic Complications
There were modest gender differences in the severity of the
hepatic steatosis and hypertriglyceridemia. Male Agpat2/
mice had 6.4-fold higher liver TG concentrations than wild-type
males, but in female Agpat2/ mice, the liver TG content was
increased only 2.1-fold (Table 1). Plasma TG concentrations
were also significantly elevated in the males but not in female
Agpat2/ mice (Table 1).
Severe insulin resistance and diabetes mellitus, additional
hallmarks of CGL, were recapitulated in both genders of
Agpat2/ mice with markedly elevated plasma glucose and
insulin levels (Table 1). Plasma free fatty acid (FFA) concentra-
tions were unchanged in male Agpat2/ mice compared to the
wild-type mice and were significantly lower in the Agpat2/
female mice (Table 1).
Energy Expenditure and Activity Studies
Energy and water consumption, CO2 production, O2 consump-
tion, and respiratory exchange ratios (RER) were determined in
the wild-type and Agpat2/mice over 72 hr in metabolic cages
and were adjusted for the 5.7% increase in lean body mass
of the Agpat2/ mice (Figures 1D–1G). The Agpat2/ mice
consumed 85% more energy and 3.7 times more water than
the wild-type mice during the light period (Figures 1D and 1E).
(D–I) Energy intake (D), water intake (E), O2 consumption (F), CO2 production (G), respiratory exchange ratio (RER) (H), and RER time course (I) in wild-type (unfilled
bars and hatched bars for the day and night data, respectively) and Agpat2/mice (filled gray and black bars for the day and night data, respectively). The data
are normalized to lean bodymass, which was 5.7% greater inAgpat2/mice. Bars represent themean and SEM. * indicates p < 0.05 in the comparison between
the two genotypes for the same period (day or night).Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc. 167
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Lipodystrophy in AGPAT2-Deficient MiceThese differences were maintained in the dark period, although
they were less pronounced. The near-absence of plasma leptin
(Table 1) in Agpat2/ mice was likely responsible for the
extreme hyperphagia. The knockout mice also consumed 24%
more O2 and emitted 22% more CO2 than the wild-type mice
(Figures 1F and 1G). The RER was significantly reduced in the
knockout mice, particularly during the dark phase, suggesting
preferential metabolism of fat or a defect in the metabolism of
carbohydrates (Figure 1H). Interestingly, the daily excursions in
the RER were blunted in the knockout mice, indicating a failure
to utilize the ingested carbohydrate as the predominant energy
source in the feeding period (Figure 1I). Compared to the wild-
type mice, Agpat2/ mice had reduced activity (Figures S7A
and S7B) especially during the dark cycle, possibly due to leptin
deficiency, which is associated with reduced locomotor activity
(Mesaros et al., 2008).
Molecular Basis of Hepatic Steatosis
and Insulin Resistance
To investigate the molecular basis of the insulin resistance, the
mRNA and protein levels of insulin receptor (INSR), insulin
receptor substrate 1 (IRS1), and IRS2 were measured in livers
of Agpat2/ mice. While the mRNA levels of the Insr and Irs1
were essentially unchanged, Irs2mRNA levels were significantly
reduced (60%–70%) in both sexes of Agpat2/ mice (Table 2).
However, INSR (40%), IRS1 (30%), and IRS2 (85%) protein
levels were significantly reduced in Agpat2/ mouse livers
(Figures 2A and 2B). These results provide a potential mecha-
nism by which insulin signaling in the livers of AGPAT2-deficient
mice is impaired.
To study the molecular basis of hepatic steatosis, we
measured the mRNA levels of genes involved in fat and glucose
metabolism (Table 2). First, we determined whether there was
a compensatory increase in the expression of other confirmed
and putative Agpat genes in Agpat2/ livers. The mRNA levels
of Agpat1 were modestly increased (1.7-fold) in the Agpat2/
males, but not in the females. Agpat3 was slightly increased in
both Agpat2/ sexes, whereas Agpat4 expression remained
undetectable. Agpat5was increased (1.6-fold) only in Agpat2/
male mice. Agpat6/Gpat4 and Agpat7/Lpeat2 were not signif-
icantly changed, but interestingly, Agpat8/Alcat1 was increased
by 4.6- and 1.6-fold in Agpat2/ males and females, respec-
tively. However, total AGPAT enzymatic activity as measured
by the conversion of [3H]LPA to PA was still reduced by 90%
in the liver homogenates of the Agpat2/ mice compared to
wild-type mice (Figure 1B), confirming that AGPAT2 is respon-
sible for the majority of this activity in the murine liver.
We next determined whether TG accumulation in the livers of
Agpat2/ mice occurred preferentially through the glycerol-3-
phosphate pathway or the monoacylglycerol (MAG) pathway or
whether dietary TGs were contributing via chylomicron remnant
uptake through receptor-mediated endocytosis (Figure 2C). The
mRNA level of the enzyme catalyzing the first step in glycerol-3-
phosphate pathway, glycerol-3-phosphate acyltransferase 1
(GPAT1), was increased 4.7-fold; however, the mRNA levels of
the enzyme catalyzing the final TG assembly in this pathway,
diacylglycerol (DAG) acyltransferase 2 (DGAT2), remained
unchanged. The mRNA expression of Dgat1 was undetectable.
On the other hand, the mRNA expression of a key enzyme168 Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Ininvolved in an alternative pathway of TG biosynthesis, MAG acyl-
transferase 1 (MGAT1), was markedly upregulated: 48-fold in
males and 25-fold in the female Agpat2/mice livers. Similarly,
the MGAT1 protein levels were increased 7.3- and 5.4-fold in the
livers of Agpat2/ male and female mice, respectively
(Figure 2D). The expression of Mgat2 mRNA was undetectable.
MGATs convert MAGs to DAGs, which can be further acylated
by DGATs to form TGs (Figure 2C). However, LPA needs to be
dephosphorylated to MAG before it can be used as a substrate.
Therefore, we investigated whether various phosphatases
potentially capable of dephosphorylating LPA to MAG were
also upregulated. These enzymes include two types of phospha-
tidic acid phosphatases (PAPs): type 1, which include lipins 1, 2,
and 3; and type 2, which include lipid phosphate phosphatases
(LPPs) 1, 2, and 3 (Brindley, 2004; Brindley andWaggoner, 1998;
Carman and Han, 2006; Donkor et al., 2007). Recent data
suggest that lipins can dephosphorylate PA but have no signifi-
cant activity for LPA (Donkor et al., 2007). On the other hand,
LPPs show less substrate preference and can dephosphorylate
both LPA and PA (Brindley and Waggoner, 1998).
Our data revealed that in male and female Agpat2/ mice,
hepatic mRNA levels of LPP1 isoform 1, were increased 2.0-
and 1.5-fold; LPP2, 3.4- and 2.0- fold; and lipin 3, 2.6- and 2.1-
fold, respectively (Table 2). Interestingly, lipins 1 and 2 were
increased only in Agpat2/ females.
In the livers of male and female Agpat2/ mice, the mRNA
levels of lipogenic genes involved in fatty acid synthesis, such
as ATP citrate lyase, acetyl-CoA carboxylase 1 (Acc1), fatty
acid synthase (Fas), elongation of very long chain fatty acids,
family member 6 (Elovl6), and stearoyl-CoA desaturase 1
(Scd1), were increased 3.1- to 9.9-fold (Table 2). There was
also a robust, 58-fold, increase in Scd2 expression in these
livers. The mRNA levels of enzymes that produce NADPH, malic
enzyme, glucose-6-phosphate dehydrogenase, and 6-phospho-
gluconate dehydrogenase were also significantly increased (2.6-
to 7-fold).
Genes involved in hepatic lipogenesis are transcriptionally
regulated by sterol response element-binding protein-1c
(SREBP-1c) (Horton, 2002), carbohydrate response element-
binding protein (ChREBP) (Uyeda and Repa, 2006), and liver X
receptor (LXR)-a (Joseph et al., 2002). Interestingly, in the
Agpat2/ mice, the hepatic levels of Srebp-1c mRNA were
slightly increased only in males (Table 2), and more importantly,
the transcriptionally active nuclear form of the SREBP-1 protein
was not increased in either sex (Figure 3A). On the other hand,
although the mRNA levels for Chrebp were reduced in livers of
Agpat2/ mice (0.6- to 0.7-fold), as was the total amount of
nuclear protein (Figure 3A), the mRNA of the specific ChREBP
target gene, L-pyruvate kinase (L-Pk), was increased (3-fold).
Finally, the mRNA levels of LXR-a and -b were not changed,
and the expression of classical LXR target genes were either
not changed or slightly decreased in Agpat2/ livers (Table 2).
Peroxisome proliferator-activated receptor (PPAR)g, another
transcription factor implicated in lipogenesis, was increased
3.1- and 1.5-fold in themale and femaleAgpat2/mice, respec-
tively; however, its transcriptional activation is a ubiquitous
feature of all steatotic livers (Browning and Horton, 2004).
To determine whether the increases in hepatic mRNA levels of
lipogenic genes observed in Agpat2/mice reflected increasedc.
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Lipodystrophy in AGPAT2-Deficient MiceTable 2. Relative Expression of Liver mRNAs of Male and Female
Agpat2/ Mice
Genotype Agpat2/ Agpat2/
Sex Male Female
mRNA Fold change Fold change
Fatty acid and TG synthesis
ATP citrate lyase 5.1 ± 1.1* 3.1 ± 0.8*
Acc1 5.5 ± 0.6* 3.9 ± 0.6*
Fas 9.9 ± 0.8* 4.7 ± 0.7*
Elovl6 9.3 ± 0.8* 4.9 ± 0.6*
Scd1 5.7 ± 0.7* 4.2 ± 0.3*
Scd2 57.7 ± 9.4* 55.5 ± 4.1*
Agpat1 1.7 ± 0.04* 1.2 ± 0.1
Agpat2 0 0
Agpat3 1.5 ± 0.1* 1.4 ± 0.1*
Agpat4 ND ND
Agpat5 1.6 ± 0.1* 1.3 ± 0.1
Agpat6/Gpat4 0.8 ± 0.05 0.9 ± 0.1
Agpat7/Lpeat2 1.8 ± 0.2 1.6 ± 0.3
Agpat8/Alcat1 4.6 ± 0.9* 1.6 ± 0.1*
Mgat1 47.7 ± 7.1* 24.5 ± 2.6*
Mgat2 ND ND
Dgat1 ND ND
Dgat2 0.9 ± 0.01 0.7 ± 0.1
Gpat1 4.7 ± 0.5* 4.8 ± 0.9*
Pparg 3.1 ± 0.1* 1.5 ± 0.1*
Phosphatidic acid
phosphatase 2a-1 (Lpp1)
2.0 ± 0.05* 1.5 ± 0.1*
Phosphatidic acid phosphatase
2a-2 (Lpp1)
1.3 ± 0.03* 1.3 ± 0.1
Phosphatidic acid phosphatase
2b (Lpp3)
1.0 ± 0.1 0.7 ± 0.0*
Phosphatidic acid phosphatase
2c (Lpp2)
3.4 ± 0.3* 2.0 ± 0.1*
Lipin 1 0.8 ± 0.2 2.1 ± 0.2*
Lipin 2 1.3 ± 0.1 1.8 ± 0.1*
Lipin 3 2.6 ± 0.5* 2.1 ± 0.3*
Fatty acid oxidation
Ppara 1.0 ± 0.1 1.0 ± 0.1
Carnitine palmitoyl transferase 1 1.1 ± 0.1 1.2 ± 0.1
Acyl-CoA oxidase-1 1.3 ± 0.1 1.1 ± 0.1
Long-chain acyl-CoA dehydrogenase 1.6 ± 0.1* 1.0 ± 0.1
Medium-chain acyl-CoA dehydrogenase 1.9 ± 0.2* 1.0 ± 0.1
Ucp1 ND ND
Ucp2 10.4 ± 0.4* 7.4 ± 0.2*
Ucp3 ND ND
SREBP pathway
Srebp-1a 1.3 ± 0.1* 1.2 ± 0.04
Srebp-1c 1.4 ± 0.1* 0.9 ± 0.1
Srebp-2 1.3 ± 0.1* 1.0 ± 0.1
Scap 0.8 ± 0.1 0.7 ± 0.03*
Insig-1 1.4 ± 0.04* 1.4 ± 0.05
Insig-2 1.9 ± 0.1* 1.3 ± 0.3Celflux through the lipogenic pathway, we first measured the protein
levels of ACC1 and FAS by immunoblot analysis. As shown in
Figure 3B, the amount of both proteins was clearly increased in
the livers of Agpat2/ mice. Next, using [3H]2O, an 4-fold
increase in de novo hepatic fatty acid synthesis was noted in
Agpat2/ livers, and a concomitant reduction in sterol synthesis
was also observed (Figure 3C). Finally, the rates of de novo
TG synthesis in primary cultured hepatocytes isolated from
Agpat2/mouse liversbydetermining incorporationof [14C]glyc-
erol into TGswere3-fold higher than thosemeasured in hepato-
cytes from wild-type littermates (Figure 3D). Taken together,
these data suggest that elevated rates of de novo TG synthesis
contribute to the TG accumulation in Agpat2/mouse liver.
Table 2. Continued
Genotype Agpat2/ Agpat2/
Sex Male Female
mRNA Fold change Fold change
Insulin and IGF-1 signaling
Insulin receptor 0.9 ± 0.04 0.8 ± 0.1
Insulin receptor substrate-1 1.3 ± 0.2 0.9 ± 0.1
Insulin receptor substrate-2 0.4 ± 0.03* 0.3 ± 0.04*
Igf-1 0.2 ± 0.03* 0.1 ± 0.02*
Igf-1 receptor 1.5 ± 0.1* 2.0 ± 0.3*
IGF binding protein 1 7.2 ± 4.5 6.9 ± 1.5*
Glucose metabolism
Chrebp 0.6 ± 0.04 0.7 ± 0.1
Phosphoenolpyruvate carboxykinase 0.6 ± 0.1* 0.6 ± 0.2
Glucokinase 2.0 ± 0.3* 2.3 ± 0.1*
Glucose-6-phosphatase 1.8 ± 0.2 3.2 ± 0.6*
L-pyruvate kinase 3.5 ± 0.3* 3.4 ± 0.2*
NADPH-producing
Malic enzyme 5.8 ± 0.4* 4.5 ± 0.3*
Glucose-6-phosphate dehydrogenase 2.7 ± 0.2* 2.6 ± 0.2*
6-Phosphogluconate dehydrogenase 7.0 ± 0.6* 6.1 ± 0.7*
LXRs and target genes
Lxr-a 1.1 ± 0.1 1.0 ± 0.1
Lxr-b 1.3 ± 0.1 1.0 ± 0.1
Abca1 1.0 ± 0.1 1.1 ± 0.04
Abcg5 0.8 ± 0.1 0.5 ± 0.1*
Abcg8 0.5 ± 0.1* 0.5 ± 0.04*
Cyp7a1 0.6 ± 0.1 0.2 ± 0.02*
Each value represents the mean fold change (± SEM) of four individual
male or female Agpat2/ mice in comparison to respective age- and
sex-matched wild-type mice. * denotes a level of statistical significance
(Student’s t test) of p < 0.05. ND indicates very low or no expression
(Ct value > 30) in the wild-type or Agpat2/ liver. AGPAT, 1-acylgly-
cerol-3-phosphate acyltransferase; GPAT, glycerol-3-phosphate acyl-
transferase 1; ALCAT, acyl-CoA:lysocardiolipin acyltransferase; LPEAT,
ethanolamine lysophospholipid acyltrasferase.
Since publication of our paper with AGPAT8/ALCAT1 (Agarwal et al.,
2006), Tang et al. (2006) published a paper labeling NP_116106 as
Agpat8, which has later been found to have GPAT activity (Cao et al.,
2006) and was labeled as GPAT3. However, this Agpat8/Gpat3 was not
studied by us.l Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc. 169
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Lipodystrophy in AGPAT2-Deficient MiceFigure 2. Immunoblot Analysis of Insulin Receptor
(INSR), IRS1, IRS2, and MGAT1 and Models for
Cellular TG Biosynthetic Pathways in the Wild-
Type and Agpat2/ Mice
(A)Whole-cell extractswereprepared from the liversof four
wild-type and Agpat2/ female mice, and equal aliquots
(30 mg) were individually transferred to nitrocellulose
membranes, incubated with the corresponding primary
and IRDye800-conjugated secondary antibodies, and
scanned as described in the Supplemental Data. Receptor
associated protein (RAP) was used as the loading control.
(B) The absolute signal intensity of INSR, IRS1, and IRS2
was normalized to the corresponding signal of RAP, and
the mean values of the ratios were compared. Bars repre-
sent themean ± SEM. * indicates p < 0.05, Student’s t test.
(C) Pathways for hepatic TG accumulation in the wild-type
and Agpat2/ mice. The left panel shows that hepato-
cytes can potentially synthesize TG from either the glyc-
erol-3-phosphate (G-3-P) or the monoacylglycerol (MAG)
pathway and accumulate TG from receptor-mediated
uptake of chylomicron remnants. G-3-P is the initial
substrate for acylation at the sn-1 position by G-3-P acyl-
transferases (GPATs) to form 1-acylglycerol-3-phosphate
or lysophosphatidic acid (LPA). LPA is further acylated at
the sn-2 position by AGPATs to form phosphatidic acid
(PA). In the next step, the phosphate group (Pi) is removed
by type 1 phosphatidic acid phosphatases (PAPs) to
produce DAG. DAG is further acylated at the sn-3 position
by DGATs to produce TG. In addition, TG can also be
synthesized via the acylation of 1- or 2-MAG by the
enzymes MAG-acyltransferases (MGATs). Normally,
most of TG biosynthesis occurs via G-3-P pathway. In
Agpat2/ mice (right panel), the suppression of AGPAT
activity interrupts the classical G-3-P pathway, which
might result in accumulation of intracellular LPA. The
concomitant overexpression of lipid phosphate phospha-
tases (LPPs) and MGAT1 observed in livers of Agpat2/
mice could divert LPA to 1-MAGandDAG through an alter-
nate pathway, which would allow the assembly of TGs by
DGATs-mediated acylation. Additionally, the marked
reduction in the hepatic steatosis observed in Agpat2/
mice upon feeding fat-free diet suggests that dietary fat
also contributes to the accumulation of TG in the liver.
(D) Totalmembraneswere prepared from the livers of thewild-type andAgpat2/micedescribed in Table 2. Individual aliquots (30mg) ofmembraneproteinswere
transferred into nitrocellulose membranes, incubated with actin or MGAT1 primary antibodies and IRDye680- or IRDy800-conjugated secondary antibodies, and
quantified as described in the Supplemental Data. Each specific MGAT1 signal was normalized to the respective actin loading control and then normalized to the
MGAT1/actin average signal in male wild-type mice. The mean of each group is represented ± SEM. * denotes p < 0.05.Hepatic steatosis could also result from a relative reduction in
very-low-density lipoprotein (VLDL) secretion. To test this possi-
bility, lipoprotein lipase activity was pharmacologically blocked
with Tyloxapol, and VLDL secretion rates were measured in vivo.
Following Tyloxapol injection, the Agpat2/ mice accumulated
slightly more TG in plasma, suggesting that total TG secretion
from liver was not reduced in the absence of AGPAT2 (Figure S8).
Finally, given that a reduction in fatty acid oxidation might
contribute to the TG accumulation in Agpat2/ livers, we evalu-
ated the expression of genes involved in this process. Ppara,
carnitine palmitoyltransferase-1 (Cpt1), and acyl-CoA oxidase
(Aco) mRNA levels were not changed in either sex, whereas
long- and medium-chain acyl-CoA dehydrogenases (Lcad and
Mcad) were slightly increased in Agpat2/ males (Table 2).
Uncoupling proteins 1 and 3 (Ucp1 and Ucp3) were undetect-
able, but Ucp2 expression was increased 10.4- and 7.4-fold in
the male and female Agpat2/ mice, respectively; however,
total hepatic mitochondrial b-oxidation did not differ between
Agpat2/ and wild-typemice (Figure 3E). Combined, the results
suggest that reduction in fatty acid b-oxidation did not explain
the TG accumulation in Agpat2/ mouse livers.
Phospholipids and Neutral Lipid Levels in the Liver
Since PA is the substrate for various phospholipids, such as
phosphatidyl ethanolamine (PE), phosphatidyl choline (PC), and
phosphatidyl serine (PS), we determined whether the hepatic
concentrations of these phospholipid species were altered in
the Agpat2/ mice. As shown in Figures 4A and 4B, PA, PE,
PC, and PS concentrations were significantly elevated in the
livers of male Agpat2/ mice only. The levels of MAG were not
significantly different between the wild-type and Agpat2/
mice of either gender (Figures 4C and 4D), but the levels of
DAG were significantly increased only in the Agpat2/ males
(Figures 4E and 4F).170 Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc.
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Lipodystrophy in AGPAT2-Deficient MiceFigure 3. Agpat2/Mice Have No Change in Liver
Nuclear SREBPs, ChREBP Protein, and Mitochon-
drial Fatty Acid Oxidation but Have Increased
Levels of Lipogenic Proteins and Rates of Fatty
Acids and TG Synthesis
(A) Immunoblot analysis of SREBP-1, SREBP-2, and
ChREBP. Nuclear proteins were prepared from individual
livers of five male wild-type and Agpat2/ mice. Equal
aliquots from each liver were pooled, and 20 mg of nuclear
extract protein was subjected to SDS-PAGE and immuno-
blotting using anti-mouse SREBP-1, SREBP-2, and
ChREBP antibodies. The cAMP response element-
binding (CREB) protein was used as the loading control.
(B) Immunoblot analysis of ACC1 and FAS. Total cell lysate
protein was isolated from individual livers of four male
wild-type and Agpat2/ mice. Equal aliquots were
pooled, and 30 mg of protein was subjected to 8% SDS-
PAGE for immunoblot analysis. RAP was used as a control
for loading.
(C) In vivo rates of hepatic fatty acid and sterol synthesis in
ten wild-type and eightAgpat2/mice using [3H]2O. Each
bar represents the mean ± SEM. * indicates p < 0.05
between the two genotypes using Student’s t test.
(D) TG synthesis rates were determined in primary hepato-
cytes from four wild-type and Agpat2/ female mice by
measuring the incorporation of [14C]glycerol into newly
synthesized TGs. Bars represent the mean ± SEM. * indi-
cates p < 0.05 between the two genotypes using Student’s
t test.
(E) Hepatic mitochondrial b-oxidation was measured as
production of acid soluble products in wild-type and
Agpat2/ mice of both genders (n = 4 each). Bars repre-
sent mean ± SEM.Diet Study
To test whether dietary restriction of fat might reduce hepatic
steatosis in Agpat2/ mice, wild-type and Agpat2/ mice
were fed chow (6.0% fat) or a fat-free diet (0.2% fat) for 2 weeks
prior to study. The fat-free diet reduced liver weight by 28% and
hepatic TG content by 56% in the male Agpat2/ mice
compared to chow diet. In contrast, liver weights of wild-type
male mice were unchanged, but liver TG content increased
3-fold on the fat-free diet (Table 3). Similar but less dramatic
changes were found in female Agpat2/mice (Table 3). Plasma
TGandFFA levelswere reduced inboth thegenders ofAgpat2/
mice. There was a slight reduction in body weight in Agpat2/
mice fed the fat-free diet that was not statistically significant.
Interestingly, no significant changes were observed in plasma
glucose or insulin levels, indicating that hepatic steatosis was
at least partially independent of the hyperinsulinemic stimuli in
Agpat2/mice (Table 3).
The gene expression profile in the livers of the Agpat2/mice
showed that themRNAsencodinggenes involved in denovo fatty
acid synthesis were only slightly further increased in females and
were unchanged in males on the fat-free diet (Table S2), corrob-
orating a functional dissociation between the lipogenic activity
and the TG assembly in the livers of Agpat2/ mice. Interest-
ingly, the fat-free diet reduced the expression of Mgat1 by
50%–60% in the livers of Agpat2/ mice, but had no effect on
the levels ofMgat1 in the wild-type controls (Table S2).
DISCUSSION
To understand the pathophysiology of adipose tissue loss as
well as its implications on metabolic regulation, several lipody-
strophic mice have been generated over the past ten years
(Duan et al., 2007; Moitra et al., 1998; Shimomura et al., 1998).
Our mouse model of lipodystrophy is developed based upon
the genetics of human CGL and thus has direct relevance in
understanding the pathophysiology of this human disease.
TargetedgenedeletionofAgpat2 inmice resulted inacomplete
absence of both white and brown adipose tissue, confirming the
critical role of AGPAT2 in the differentiation of both types of
adipocytes. In fact, deletion of other acyltransferases involved
in the glycerol-3-phosphate pathway of TG synthesis, i.e.,
GPAT1, AGPAT6/GPAT4, DGAT1, andDGAT2, have not resulted
in severe lipodystrophy, insulin resistance, or hepatic steatosis
(Beigneux et al., 2006; Buhman et al., 2002; Hammond et al.,
2002; Smith et al., 2000; Stone et al., 2004; Vergnes et al.,
2006). Furthermore, the phenotype of Agpat2/ mice demon-
strates that other AGPAT isoforms—mainly AGPAT1, which is
also highly expressed in adipose tissue and exhibits similarCell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc. 171
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Lipodystrophy in AGPAT2-Deficient MiceFigure 4. Sexual Dimorphism in the Hepatic Lipid Composition of Agpat2/ Mice
(A and B) Hepatic concentrations of phosphatidyl ethanolamine (PE), phosphatidyl choline (PC), phosphatidic acid (PA), phosphatidyl serine (PS), and phospha-
tidyl glycerol (PG) in mmol per g of liver tissue in male and female wild-type and Agpat2/ mice. Bars represent the mean and SEM.
(C–F) Concentrations of monoacylglycerol (MAG) and diacylglycerol (DAG) in the liver homogenates from the male and female wild-type and Agpat2/mice. No
statistically significant differences were found between the female wild-type and Agpat2/ mice among the various phospholipid, MAG, and DAG species
measured. * indicates p < 0.05 for the comparison between the male wild-type and Agpat2/ mice. Bars represent the mean and SEM.acyltransferase activity in vitro—are unable to compensate for
the absence of AGPAT2.
The Agpat2/ mice, similar to patients with CGL type 1
(Chandalia et al., 1995), developed organomegaly, including
hepatosplenomegaly, nephromegaly, and elongated small intes-
tines. This phenotype might be due to a chronic activation of the
insulin-like growth factor (IGF)-1 and -2 receptors (Fradkin et al.,
1989) secondary to the extreme hyperinsulinemia developed
by the Agpat2/ mice. In support of this hypothesis, IGF-1
receptor mRNA levels were indeed increased in Agpat2/ livers
(Table 2).
Although not systematically studied, female patients with CGL
seemtodevelopmoreseveremetabolic complications thanmales
(Seip and Trygstad, 1996; Van Maldergem et al., 2002). In our
mouse model, however, the female Agpat2/ mice developed
lessseverehepaticsteatosisorhypertriglyceridemiaascompared
to their male counterparts. Both genders of Agpat2/ mice
nonetheless developed diabetes, insulin resistance, and hepato-
megaly. The gender dimorphism may suggest the role of testos-
terone and estrogen in the TG biosynthesis/metabolism in the
rodent liver.Micedeficient in the aromataseenzyme (Cyp19a1/)
have recently been reported to have increased hepatic steatosis,
which was attenuated on estrogen supplementation (Hewitt et al.,
2004; Jones et al., 2000; Murata et al., 2002). Interestingly, this
phenotype was observed in the male liver only. Additional
comparativestudiesof the liversof theAgpat2/maleand female
mice will eventually reveal a role for sex steroids and their recep-
tors in the biosynthesis of TG.
The Agpat2/ mice developed hepatic steatosis as early as
2–3weeks of age. Normally, nearly all TG synthesis in liver occurs
via the glycerol-3-phosphate pathway, whereas the MAG
pathway remains inactive. Interestingly, despite an increase in
expression of AGPATs 1, 3, and 8/ALCAT1, the total AGPAT
activity remained diminished in the Agpat2/ mouse livers. In
addition, an 5-fold increase was noted in the mRNA for Gpat1,
but no significant increases in the expression of Dgats were172 Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc.
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Lipodystrophy in AGPAT2-Deficient MiceTable 3. Phenotypic Comparison of Male and Female Wild-Type and Agpat2/ Mice Fed Chow or a Fat-Free Diet for 2 Weeks
Wild-type Agpat2/
Gender Male Female Male Female
Diet
Chow
(6% fat)
Fat-free
(0.2% fat)
Chow
(6% fat)
Fat-free
(0.2% fat)
Chow
(6% fat)
Fat-free
(0.2% fat)
Chow
(6% fat)
Fat-free
(0.2% fat)
Number 6 5 4 4 5 6 4 5
Age (weeks) 11–14 9.5–11.5 27–28 26–29 12–15 9.5–11.5 27–29 27–29
Body weight (g) 28.3 ± 3.0 25.5 ± 3.9 21.9 ± 0.75 23.8 ± 1.6 28.7 ± 4.5 22.2 ± 5.0 22.3 ± 2.6 17.6 ± 0.36
Liver weight (g) 1.50 ± 0.18 1.51 ± 0.20 0.98 ± 0.08 1.37 ± 0.29 4.56 ± 1.23 3.30 ± 1.16 3.60 ± 0.73 2.73 ± 0.25
Liver TG (mg/g) 5.72 ± 1.6 16.8 ± 5.26 14.9 ± 4.1 29.0 ± 10 51.7 ± 18.4 22.6 ± 7.43 49.3 ± 9.1 24.7 ± 9.32
Plasma TG (mg/dl) 100 ± 39 118 ± 31 68.0 ± 3.7 77.0 ± 28 194 ± 26 45.1 ± 1053 156 ± 101 41.2 ± 31.71
Insulin (ng/ml) 2.06 ± 1.06 2.70 ± 1.34 1.30 ± 0.062 1.82 ± 0.62 59.0 ± 36 79.6 ± 80 58.1 ± 11 40.3 ± 16
Glucose (mg/dl) 255 ± 20 281 ± 19 297 ± 18 322 ± 41 591 ± 87 443 ± 156 425 ± 84 391 ± 141
Free fatty acids (mEq/l) 0.57 ± 0.19 0.63 ± 0.12 0.37 ± 0.06 0.34 ± 0.08 0.43 ± 0.09 0.21 ± 0.043 0.37 ± 0.08 0.23 ± 0.052
Wild-type and Agpat2/mice of both sexes were fed ad libitum a rodent chow that contained 6.0% fat or a fat-free diet (0.2% fat) for 2 weeks. Each
value represents the mean ± SD. 1p = 0.05, 2p < 0.05; and 3p < 0.01 between the chow diet and the fat-free diet for the same genotype and gender.noted. Thus, it seems that compensatory increases in the other
acyltransferases implicated in theglycerol-3-phosphate pathway
may not have a significant role in TG synthesis (Figure 2C).
The entire de novo fatty acid synthetic program was activated
in Agpat2/ mouse livers (Table 2 and Figures 3A and 3B). The
elevated lipogenesis in Agpat2/ mouse livers resembles the
findings in previous hyperinsulinemic-hyperglycemic hepatic
steatosis murine lipodystrophy models (Moitra et al., 1998; Shi-
momura et al., 1999); however, the exact mechanism underlying
the transcriptional activation of the lipogenic genes in Agpat2/
livers remains unclear, since neither SREBP-1c mRNA nor
nuclear protein was elevated, as has been previously demon-
strated (Moitra et al., 1998; Shimomura et al., 1999) (Table 2
and Figure 3A). Furthermore, the amount of nuclear ChREBP
was reduced in Agpat2/ mouse livers (Figure 3A); however,
the mRNA level of L-Pk, a ChREBP-regulated gene, was
increased. Therefore, a potential role of ChREBP in activating
lipogenesis cannot be completely excluded, since the transcrip-
tional activity of ChREBP is also regulated by phosphorylation
(Uyeda and Repa, 2006). Finally, it is also possible that the
2-fold increase in PPARg mRNA (Table 2) contributes to the
activation of lipogenesis in Agpat2/mouse livers, but whether
this is the only mechanism will require further study.
Mgat1 is reportedly expressed in the stomach, kidney, and
adipose tissue, and at low levels in the liver. On the other hand,
Mgat2 is predominantly expressed in the small intestine (Cao
et al., 2003, 2004; Yen and Farese, 2003; Yen et al., 2002). In
our studies, Mgat1 mRNA levels were very low in the livers of
wild-type mice (Ct value > 30); however, the deletion of Agpat2
was associated with a robust 25- to 48-fold induction of Mgat1
mRNA (Table 2) and 5- to 7-fold increase in MGAT1 hepatic
protein (Figure 2D), suggesting that enhanced TG synthesis can
occur via this alternate MAG pathway in the livers of Agpat2/
mice, such as we previously proposed (Agarwal and Garg,
2003). Unfortunately, our attempts to measure MGAT enzymatic
activity in the liver homogenates aswell as in isolatedmicrosomal
preparation failed, most likely due to abundant activity of lipases.
The reduction in total AGPAT activity observed in Agpat2/
livers (Figure 1B) may result in accumulation of LPA. This
phospholipid can subsequently be converted into MAG byCedephosphorylation mediated by type 2 PAPs. Indeed, the
mRNA of type 2 PAPs known to dephosphorylate LPA, such as
Lpp1 isoform 1 and Lpp2, were upregulated in the liver of
Agpat2/mice (Table 2). Although lipin 3was also upregulated,
it has not been shown to have phosphatase activity against LPA
(Donkor et al., 2007). The PAPs localize to plasma membrane,
endoplasmic reticulum, and perhaps nucleus (Carman and
Han, 2008; Sigal et al., 2005). However, how increased expres-
sion of some of these phosphatases will influence conversion
of LPA to MAG requires further study. Overall, these data
suggest that the alternate MAG pathway is activated in the
liver of Agpat2/ mice, and that it could be a mechanism for
TG accumulation in these animals (Figure 2C).
Elevated concentrations of PC, PE, and PS in the liver of male
Agpat2/ mice may also be explained by increased biosyn-
thesis of DAG through the MAG pathway. In the female
Agpat2/ mice, the increases in PC, PE, and PS were not
statistically significant. Male Agpat2/ mice also had higher
hepatic levels of DAG compared to the wild-type male mice. It
is possible that increased PA levels may be related to conver-
sion of some DAG to PA by DAG kinase. The siRNA-mediated
knockdown of AGPAT2 in TG-depleted cultured adipocytes
increased the levels of several phospholipids and prevented
adipocyte differentiation (Gale et al., 2006); however, the molec-
ular mechanism underlying this phenomenon remains unknown.
It will be interesting to determine how the higher levels of PE,
PC, and PS contribute to the increased TG retention in the
hepatocytes.
Feeding a fat-free diet resulted in an 50% reduction in the
liver TG concentration in Agpat2/ mice (Table 3). This finding
suggested that a significant proportion of the hepatic pool of
TG comes from diet as chylomicron remnants, and that the
increased de novo lipogenesis measured in Agpat2/ mice on
chow is at least partially uncoupled from TG synthesis when
the mice are fed a fat-free diet, since lipogenic gene expression
is still elevated (Table S2). In contrast, wild-type mice accumu-
lated hepatic TG when fed the fat-free diet, most likely due to
the high carbohydrate intake, which induces de novo lipogenesis
through the activation of SREBP-1c and ChREBP (data not
shown). In normal mice, the resulting increased fatty acidll Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier Inc. 173
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Lipodystrophy in AGPAT2-Deficient Micesynthesis is normally coupled to TG synthesis, which leads to the
increase in TG accumulation.
Agpat2/mice developed a severe whole-body insulin resis-
tance, and reduced expression of Insr, Irs1, and Irs2 might be
responsible for hepatic insulin resistance in the Agpat2/
mice, a finding that is consistent with previous observations (Shi-
momura et al., 2000). The observed islet hypertrophy is likely
a compensatory phenomenon in response to severe insulin
resistance. Interestingly, insulin resistance was present despite
normal or low levels of serum FFAs, in contrast to normal or
high serum FFA levels in all other mousemodels of lipodystrophy
associated with hepatic steatosis (Moitra et al., 1998; Shimo-
mura et al., 1998). This finding challenges the notion that high
serum FFA levels are required to induce hepatic or peripheral
insulin resistance. Thus, lipodystrophy in Agpat2/ mice may
induce hepatic steatosis and insulin resistance by diverting die-
tary TG for deposition in the liver. In fact, other mechanisms such
as intrahepatic or intramyocellular accumulation of TGs or other
intermediates in the TG biosynthetic or oxidation pathway, such
as DAG or ceramides, may also be important (Holland et al.,
2007; Nagle et al., 2007; Unger, 2003); however, we observed
only a mild increase in the DAG content in the livers of male,
but not female, Agpat2/ mice.
Finally, the profound hypoleptinemia observed in Agpat2/
mice can explain both the sustained hyperphagia and the
reduced locomotor activity observed in these animals (Mesaros
et al., 2008). The analysis of the RER revealed that the lipody-
strophic mice rely more on oxidation of fat as an energy source,
and that they manifest a relative inability to utilize carbohydrates
as the primary energy substrate in the fed state. This observation
is consistent with whole-body insulin resistance and the resulting
inability of tissues to take up glucose. The hyperphagia may also
be further exaggerated by the complete loss of adipose tissue,
which contributes to excessive loss of heat in the lipodystrophic
mice. These observations also suggest that the human infants
with CGL type 1 may also lack brown adipose tissue and thus
the ability to regulate body temperature when required. The
striking increase in Ucp2 mRNA levels in the liver suggests that
some compensatory thermogenesis is occurring there.
In summary, Agpat2/ mice replicate the phenotype of CGL
in humans and thus represent a unique in vivo model that may
be exploited in future studies to elucidate the biochemical link
between the TG synthesis pathway and adipogenesis in the liver
and adipose tissue. Our data provide evidence for the potential
role of activation of the alternative MAG pathway for hepatic
TG biosynthesis in causing hepatic steatosis in these mice.
Furthermore, we show that reduction in dietary fat mitigates
hepatic steatosis in Agpat2/ mice, suggesting that dietary fat
contributes significantly to hepatic accumulation of TGs.
EXPERIMENTAL PROCEDURES
Agpat2 Deletion Strategy
Details of targeting vector construction, ES culture, Agpat2/ mice genera-
tion, and genotyping are in the Supplemental Data.
Biochemical Measurements
Plasma concentrations of TGs, insulin, glucose, FFAs, and liver TGs were
measured as previously described (Engelking et al., 2004; Ishibashi et al.,
1993; Matsuda et al., 2001).174 Cell Metabolism 9, 165–176, February 4, 2009 ª2009 Elsevier InAntibodies and Immunoblot Analysis
The following rabbit polyclonal antibodies were used for immunoblot analysis:
ACC1 and FAS (Genepia; Seoul, South Korea), ChREBP (Novus Biologicals;
Littleton, CO), INSR (BD Transduction Laboratories; San Jose, CA), IRS1
and IRS2 (Upstate; Temecula, CA), MGAT1 (M-90, Santa Cruz Biotechnology;
Santa Cruz, CA), and SREBP-1 and SREBP-2 (Shimano et al., 1996, 1997).
Details of immunoblots are presented in the Supplemental Data.
Real-Time Reverse Transcriptase-PCR
Total RNA was prepared frommouse livers using RNA STAT-60 (Tel-Test, Inc.;
Friendswood, TX). All RT-PCRs were carried out in 384-well plates using the
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems), as
reported previously (Liang et al., 2002; Yang et al., 2001). Primers used for
additional genes are listed in Table S3.
Metabolic Rate Measurements
Indirect calorimetry, heat production, and movement were measured in six
12-week-old wild-type female mice and five 12-week-old Agpat2/ female
mice using Comprehensive Lab Animal Monitoring System (CLAMS) open-
circuit Oxymax system (Columbus Instruments; Columbus, OH). Mice were
individually housed in plexiglass cages, through which air of known
O2 concentration was passed at a constant flow rate. After a 48 hr acclimation
period, exhaust air was sampled intermittently for 72 hr for the determination of
O2 and CO2. Mice were fed ad libitum, and all measurements were adjusted
by the calculated lean mass.
In Vivo Fatty Acid and Sterol Synthesis
Hepatic fatty acids and sterol synthesis were measured in 12-week-old ad
libitum-fed littermates (ten wild-type, eight Agpat2/) by administering
50mCi [3H]2O intraperitoneally, as previously described (Shimano et al., 1996).
TG Synthesis Rates in Cultured Hepatocytes
TG synthesis rate was measured by incubating primary hepatocytes isolated
from nonfasted wild-type (n = 4) or Agpat2/ (n = 4) mice with [14C]glycerol
(Horton et al., 1999). Details are in the Supplemental Data.
b-Oxidation in Liver Mitochondria
Mitochondria were isolated from the livers of 5- to 8-week-oldmale and female
wild-type and Agpat2/ mice. Oxidation of [14C]oleate was measured as
conversion to acid soluble products, as described previously (McGarry
et al., 1978).
AGPAT Activity in Liver Homogenates
Total AGPAT enzymatic activity was determined as described previously
(Haque et al., 2005). Details are in the Supplemental Data.
Neutral Lipids and Phospholipids in Liver Homogenates
Total lipids from the liver (0.18 g wet weight) were essentially extracted as
described earlier (Markham et al., 2006). The details of measurement of neutral
lipids and phospholipids are provided in the Supplemental Data.
Statistical Analysis
For experiments comparing genotype and sex on a chow diet, two-way
ANOVA was performed. To compare genotype, sex, and the regular chow
versus fat-free diets, three-way ANOVAwas performed. Sincemost of the vari-
ables were skewed, and heterogeneity of variances was observed, the data
were rank transformed prior to analysis. Adjustments for multiple comparisons
were made using the adjust = simulate option of the Generalized Linear Model
procedure in Statistical Analysis System (SAS). Statistical analysis was
performed using SAS version 9.1.3 (SAS Institute; Cary, NC).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, eight figures, and three tables and can be found online at
http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)00003-5.c.
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